Current status of methods to assess cancer drug resistance.
about
Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapyTranslational imaging endpoints to predict treatment response to novel targeted anticancer agents.MicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells.EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 functionMolecular targeted approaches for treatment of pancreatic cancer.Mechanisms and insights into drug resistance in cancerCould a revision of the current guidelines for cancer drug use improve the quality of cancer treatment?Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma.A short update on cancer chemoresistance.Distinctive behaviour of live biopsy-derived carcinoma cells unveiled using coherence-controlled holographic microscopy.The ability of hyaluronan fragments to reverse the resistance of C6 rat glioma cell line to temozolomide and carmustine.BMS-536924, an ATP-competitive IGF-1R/IR inhibitor, decreases viability and migration of temozolomide-resistant glioma cells in vitro and suppresses tumor growth in vivo.Mesenchymal stem cell-mediated cancer therapy: A dual-targeted strategy of personalized medicine.Correspondence (letter to the editor): Laboratory tests to ascertain tumor resistance to drugs are available.The effect of intrinsic and acquired resistances on chemotherapy effectiveness.Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients.
P2860
Q26779938-5AE0C9FC-1B42-41D7-9179-8424B7A664CBQ30465097-BAB786D0-8EF6-40D9-A671-8A22C8D6E932Q35766816-C43B411E-0068-45A8-BEC8-CECC1C0B4BECQ35895556-1DFAA515-8A6F-49BB-8E4D-83F027C10C70Q36174910-593A775C-AD52-463C-B8EB-E6EAB7AEC8DAQ36682301-E2038AB4-38A8-40AE-A4F1-D236D744E126Q37554234-82A5BCAF-78D3-4E67-91B7-98D42802C00BQ37634419-36D44F58-1518-4778-B82C-A432AAFD6223Q38253576-73ABC02E-EA44-4B71-B397-3F55C9DEBD27Q38636694-09F97B23-B61A-49F5-AE14-FA3FFD0F8FBCQ38932015-6AFBB90C-156C-4ED6-9693-2E9CC739D1C5Q39620395-7FEDACE0-3B29-4A8F-9ED1-68F5312F747FQ39863924-8BBD1883-047B-4414-80E9-5420F3E840FEQ42560218-0BED0A29-1767-4E83-8B15-3D6168C7DED0Q50951071-F42AEDEB-6F83-4FA6-8111-904F8ADB5D04Q54333038-F3E0976C-6370-4A09-9294-0C49174CB559
P2860
Current status of methods to assess cancer drug resistance.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Current status of methods to assess cancer drug resistance.
@ast
Current status of methods to assess cancer drug resistance.
@en
Current status of methods to assess cancer drug resistance.
@nl
type
label
Current status of methods to assess cancer drug resistance.
@ast
Current status of methods to assess cancer drug resistance.
@en
Current status of methods to assess cancer drug resistance.
@nl
prefLabel
Current status of methods to assess cancer drug resistance.
@ast
Current status of methods to assess cancer drug resistance.
@en
Current status of methods to assess cancer drug resistance.
@nl
P2093
P2860
P356
P1476
Current status of methods to assess cancer drug resistance.
@en
P2093
Hans-Jörg Ruoff
Manfred Volm
Theodor H Lippert
P2860
P304
P356
10.7150/IJMS.8.245
P407
P5008
P577
2011-03-23T00:00:00Z